[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medtronic MiniMed, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":146},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,67,78,103,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053900","gateway-safety-evaluation-of-the-minimed-nmx8-aid-system-in-children-and-adults-living-with-diabetes-100053900",false,"NCT07228117","GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes","Inclusion Criteria:\n\n1. Age at time of screening according to diabetes type:\n\n   1. T1D: Age 7-85 years\n   2. T2D: Age 18-85 years\n2. Has a clinical diagnosis of diabetes for a minimum per diabetes type below:\n\n   1. T1D (Age 7-85 years): Diagnosis of T1D for at least 6 months, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.\n   2. T2D (Age 18-85 years): Diagnosis of insulin-requiring T2D for 1 year or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis\n3. Is willing to provide informed consent\u002Fassent for participation.\n4. Subject or parent\u002Fcaregiver is literate and able to read the language (English or Spanish) offered in the study pump or study pump materials.\n5. Is willing to wear the system continuously throughout the study.\n6. Has results of a retinal eye examination on record prior to enrollment, per guidelines by the American Diabetes Association according to age, duration of diabetes and type of diabetes:\n\n   1. T1D adults (Age 18-85 years):\n\n      I. Initial retinal eye exam within 5 years of diagnosis. II. If the duration of type 1 diabetes is longer than 5 years, a retinal examination should have been performed within the last 12-18 months.\n   2. T2D adults (Age 18-85 years):\n\n      I. Results of a retinal eye exam, performed within the last 12-18 months, should be on record.\n   3. T1D pediatric (Age 7-17 years):\n\n   I. No exam is required if under the age of 10 years unless the duration of diabetes is more than 3 years.\n\n   II. For children over the age of 10, a retinal exam should have been performed within 24 months of enrollment in the study.\n\n   Per the investigator's discretion: If a potential participant is deemed to be at high risk, a retinal eye exam, performed within the last 12 months prior to screening, should be on record.\n7. Is willing to upload study pump data via an app or computer.\n8. Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:\n\n   1. Humalog™\\* (insulin lispro injection)\n   2. NovoLog™\\* (insulin aspart solution for injection) or an interchangeable biosimilar (for example, Kirsty™\\*)\n   3. NovoRapid™\\* (insulin aspart solution for injection)\n   4. Admelog™\\* (insulin lispro injection)\n   5. Merilog™\\* (insulin aspart)\n   6. Fiasp™\\* (ultra-rapid-acting insulin aspart)\n   7. Lyumjev™\\* (ultra-rapid-acting insulin lispro)\n   8. Authorized generic insulin aspart\n   9. Authorized generic insulin lispro\n\nExclusion Criteria:\n\n1. Unable to consent due to a mental or intellectual disability.\n2. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following, during the 6 months prior to screening:\n\n   1. Medical assistance (i.e., Paramedics, Emergency Room \\[ER\\] or Hospitalization)\n   2. Coma or\n   3. Seizures\n3. Has a history of 1 or more episodes of diabetic ketoacidosis (DKA) in the last 6 months prior to screening visit.\n4. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.\n5. Has any unresolved adverse skin condition in the area of sensor or infusion set placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).\n6. Currently pregnant or planning to become pregnant during the time period of study participation\n\n   1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening\n   2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable\n7. At investigator discretion, has hypothyroidism or hyperthyroidism that is not adequately treated.\n8. Has diagnosis of adrenal insufficiency.\n9. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit.\n10. T1D: Is using non-insulin anti-hyperglycemic medication, other than metformin and\u002For Glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) containing medications (e.g., Mounjaro), in the 8 weeks prior to screening.\n\n    1. Participants who have stopped using metformin and\u002For GLP-1\u002FGIP have done so at least 8 weeks prior to screening.\n    2. Participants currently taking metformin and\u002For GLP-1\u002FGIP must be on a steady dose and remain on the same dose during study participation. Dose changes and reasons for changes will be documented throughout the study.\n11. T2D: Is using non-insulin anti-hyperglycemic medication, other than metformin, GLP-1 \u002FGIP containing medications (e.g., Mounjaro), or Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, in the 8 weeks prior to screening.\n\n    1. Participants who have stopped using metformin, GLP-1\u002FGIP or SGLT2 have done so at least 8 weeks prior to screening.\n    2. Participants currently taking metformin, GLP-1\u002FGIP or SGLT2 must be on a steady dose and remain on the same dose during study participation. Dose changes and reasons for changes will be documented throughout the study\n12. Is using sulfonylureas and meglitinides, e.g., repaglinide, in the 8 weeks prior to screening.\n13. Is using inhalable insulin in the 8 weeks prior to screening.\n14. Is using hydroxyurea at time of screening or plans to use it during the study\n15. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study.\n16. Is, at the discretion of the investigator, abusing drugs or alcohol.\n17. Is, in the opinion of the investigator, not able to perform all study procedures safely.\n18. Has a history of visual impairment which would not allow subject, even with the help of a caregiver, to participate in the study and perform all study procedures safely, as determined by the investigator.\n19. Has elective surgery planned that requires general anesthesia during the course of the study.\n20. Has sickle cell disease or other hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.\n21. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.\n22. Is diagnosed with current eating disorder such as anorexia or bulimia.\n23. Blood disorder or dyscrasia within 3 months prior to screening, which in the investigator's opinion could interfere with determination of HbA1c\n24. Is on dialysis.\n25. Has an estimated Glomerular Filtration Rate (eGFR) \\\u003C30.\n26. Has celiac disease that is not adequately treated as determined by the investigator.\n27. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.\n28. Has had any of the following cardiovascular events more than 1 year prior to screening and should not participate at the discretion of the investigator: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.\n29. Is a member of the research staff involved with the study.\n30. Is a Medtronic Diabetes employee or their immediate family member (excluding adult children and\u002For adult siblings).","ALL","7 Years","85 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5\u002FSimplera Sync in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Participants will use their current therapy while also wearing the DS5\u002FSimplera sensor for up to 40 days. During this time, they will complete a meal and exercise log. Participants will then be placed into one of three groups by chance and given the NMX8 pump to use for about 90 days. During this time, participants will bolus, not bolus, or bolus at will for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if participants like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.",[26,27],"Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-02-02",{"date":36,"type":20},"2027-01",{"name":38,"class":39},"Medtronic MiniMed, Inc.","INDUSTRY",38,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100645041","minimed-fit-payload-wear-pediatric-study-100645041","NCT07675161","MiniMed Fit Payload Wear Pediatric Study","CIP361: MiniMed Fit Payload Wear Pediatric Study","Inclusion Criteria:\n\n* Participants with insulin-requiring diabetes\n* Participants 7-17 years of age\n* Participant and parent\u002Fguardian\u002Flegally authorized representative are able and willing to sign informed consent\u002Fassent\n\nExclusion Criteria:\n\n* Participants who report known skin sensitivity or allergy to polycarbonate or pressure-sensitive adhesives, e.g., medical device adhesives, band-aids, other acrylic-containing adhesives.\n* Participants with any skin condition in the area where device placement (e.g., irritation, rash, infection) could occur, per participant report.\n* Participants who are pregnant (per self-report) at initial screening. If a participant becomes pregnant during the study, the site will follow procedures for study withdrawal.","17 Years",{"count":50,"type":20},100,"OBSERVATIONAL","The purpose of this study is to assess MiniMed Fit Payload adhesive components in different wear locations over a 7-day period to support development of the future commercialized patch pump in participants 7-17 years of age.",[54,55,56,57],"Diabetes (DM)","Diabetes (Insulin-requiring, Type 1 or Type 2)","Diabetes in Children","Diabetes in Adolescence","NOT_YET_RECRUITING","2026-06-25",{"date":61,"type":32},"2026-06-30",{"date":63,"type":20},"2026-07",{"date":65,"type":20},"2026-12",{"name":38,"class":39},{"id":68,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":24,"conditions":71,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":77,"locationsCount":40},"100610479",{"count":19,"type":20},[23],[26,27],"2026-06-04",{"date":74,"type":32},"2026-06-08",{"date":34,"type":32},{"date":36,"type":20},{"name":38,"class":39},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100623843","evaluation-of-the-safety-and-effectiveness-of-the-novel-medtronic-experimental-automated-insulin-delivery-system-nmx8-in-adults-living-with-type-1-diabetes-100623843","NCT07401901","Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes","ELEVATE","Inclusion Criteria:\n\n1. Is aged ≥ 18 years old at time of screening.\n2. Has a clinical diagnosis of Type 1 diabetes for ≥6 months prior to screening as determined via medical record by an individual qualified to make a medical diagnosis.\n3. Is on commercially approved AID therapy (e.g. MiniMed 780G, Control IQ, OmniPod 5, CamAPS FX) for at least 3 months before screening.\n4. Has a glycosylated hemoglobin (HbA1c) above ≥7.5 % (59 mmol\u002Fmol), therefore is not achieving therapy goal, at time of screening visit (as processed by a Central Lab).\n5. Must have a minimum daily insulin requirement (Total Daily Dose) of ≥ 6 units and a maximum of 250 units.\n6. Has shown good compliance (≥70%) with sensor wear over the previous month prior to enrollment (based on sensor usage from the download summary report over the 30 days prior to enrollment).\n7. Is willing to switch to an approved insulin per insulin pump labeling.\n8. Is willing to participate in all training sessions as directed by study staff.\n9. Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol.\n10. Subject is willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Has untreated Addison's disease, thyroid disorder, growth hormone deficiency, hypopituitarism or definite gastroparesis, per investigator judgment.\n2. Is using any anti-diabetic medication other than insulin at the time of the screening or plan on using during the study (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists\u002Fmimetics, metformin, SGLT2 inhibitors).\n3. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take chronically any oral, injectable, or IV glucocorticoids during the course of the study.\n4. Has had renal failure defined by creatinine clearance \\\u003C30 ml\u002Fmin, as assessed by local lab test ≤ 6 months before screening or performed at screening at local lab, as defined by the creatinine-based Cockcroft, CKD-EPI or MDRD equations.\n5. Has any unresolved adverse skin conditions in the area of sensor placement (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).\n6. Has active or severe retinopathy in the last 6 months before the screening.\n7. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.\n8. Has a positive pregnancy test at screening or plan to become pregnant during the course of the study or is breast feeding at the time of the enrollment.\n\n   Note: Different effective contraception methods may be used such as contraceptive pills, condoms, intra-uterine device, patches, rings, or long-active reversible contraceptive methods, as per routine practice.\n9. History of 2 or more DKA events in the last 3 months before screening.\n10. Is on \"DIY\" therapy at the time of the screening or at least 3 months before the screening.\n11. Is planning to change AID therapy during the course of the study. Note: subjects randomized in the Control Arm should remain on their current therapy during the course of the study.\n12. Is actively participating in an investigational study (drug or device) wherein he\u002Fshe has received treatment from an investigational study drug or device in the last 2 weeks before enrollment into this study, as per investigator judgment.\n13. Is currently abusing illicit drugs, marijuana, alcohol or prescription drugs (other than nicotine), per investigator judgment.\n14. Is part of the research staff involved with the study.\n15. Is legally incompetent, illiterate or vulnerable person.","18 Years",{"count":87,"type":20},230,[23],"The purpose of the study is to evaluate the safety and the effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery system, named MiniMed NMX8 system (referred also to as NMX8 system), in comparison with other commercially available AID systems (Automated insulin delivery) in adult patients with Type 1 diabetes not achieving target clinical outcomes.",[91],"Type 1 Diabetes (T1D)",[93],"Automated insulin delivery (AID); Diabetes","2026-04-27",{"date":96,"type":32},"2026-04-28",{"date":98,"type":20},"2026-10-15",{"date":100,"type":20},"2028-03-29",{"name":38,"class":39},21,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":123,"locationsCount":5},"100572941","clinical-evaluation-of-the-medtronic-implantable-insulin-pump-system-miips-2020-in-adult-subjects-with-type-1-diabetes-cip347-100572941","NCT06739811","Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)","Phoenix: Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes","Phoenix CIP347","Inclusion Criteria:\n\n1. Subject is aged ≥ 18 years old.\n2. Subject has a clinical diagnosis of type 1 diabetes for ≥ 6 months prior to screening as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.\n3. Subject with type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin therapy (including external pump), presenting with frequent, otherwise unexplained severe hyper-and\u002For hypoglycaemia.\n4. Subject has access to a reliable support person, defined as an individual who has daily contact with the subject and knows who to contact in the event of an emergency (i.e., caregiver).\n5. Subject has the physical and intellectual ability (in the opinion of the study investigator) to operate the MIIP system and to comply with the data reporting requirements of the study.\n6. Subject is willing and able to sign and date informed consent, comply with all study procedures as required during the study.\n\nExclusion Criteria:\n\n1. Subject is actively participating in an investigational study (drug or device) wherein he\u002Fshe has received treatment from an investigational study drug or device before enrollment into this study, that could impact the outcomes of this study; as per investigator and sponsor judgment.\n2. Subject has any other disease or condition that may increase risks during the implant procedure or may preclude the subject from participating in the study, as determined by a physician who is not the principal investigator.\n3. Subject has any known or suspected allergy to insulin or implantable materials of the MIIPS (pump and catheter) as determined by a physician.\n4. Subject is a woman who is pregnant, of childbearing potential or lactating, and who is neither surgically sterile nor using contraceptives (devices, oral, implanted or other physician-approved contraceptive) at the time of enrollment.\n5. Subject is vulnerable, legally incompetent or illiterate.\n6. Residence or planned non-pressurized travel at elevations above 10000 feet\u002F3048 meters (commercial airline travel is acceptable).\n7. Planning to engage in activities requiring a descent greater than or equal to 10 feet\u002F3 meters below sea level.\n8. Subject has an active infection requiring antibiotic treatment.\n9. Subject is a person whose body size is not sufficient to accept implantable pump bulk and weight.\n10. Subject has a life expectancy of less than 9 months.\n11. Subject has diagnosis of illicit drugs abuse disorder.\n12. Subject has diagnosis of marijuana abuse disorder.\n13. Subject has diagnosis of prescription drugs abuse disorder.\n14. Subject has diagnosis of alcohol abuse disorder.\n15. Subject who is unwilling or unable to monitor their glucose level or wear a personal continuous glucose monitor.\n16. Subject who is unwilling or unable to make programming modifications to the pump based on glucose level readings.",{"count":112,"type":20},40,[23],"The purpose of this study is to evaluate the clinical performance of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in adult patients with Type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin therapy (including external pump), and presenting with frequent, otherwise unexplained severe hyper- and\u002For hypoglycemia.",[116],"Type I Diabetes","2026-03-20",{"date":119,"type":32},"2026-03-23",{"date":121,"type":32},"2025-03-21",{"date":65,"type":20},{"name":38,"class":39},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100610455","evaluation-of-the-safety-and-performance-of-the-novel-medtronic-experimental-automated-insulin-delivery-system-nmx8-in-people-living-with-diabetes-nexus-100610455","NCT07227805","Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)","Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes","NEXUS","Inclusion Criteria:\n\n1. Is aged ≥2 years old at time of screening.\n2. Has a clinical diagnosis of Type 1 or Type 2 diabetes for ≥ 6 months prior to screening as determined via medical record by an individual qualified to make a medical diagnosis.\n3. Is on MiniMed™ 780G with Simplera Sync sensor for at least 3 months before screening.\n4. Has a glycosylated hemoglobin (HbA1c) \\\u003C11% (97 mmol\u002Fmol) at time of screening visit as processed at Point of Care (PoC) or local lab.\n5. Must have a minimum daily insulin requirement (Total Daily Dose) of ≥ 6 units and a maximum of 250 units\n6. Willing to switch to approved insulin per insulin pump labeling.\n7. Investigator has confidence that the subject, parent(s)\u002Flegal guardian(s) can successfully operate all study devices and is capable of adhering to study visit schedule per protocol.\n8. Subject, Parent(s)\u002Flegal guardian(s) is willing to participate in all training sessions as directed by study staff.\n9. Subject, Parent(s)\u002Flegal guardian(s) is willing and able to provide written informed consent.\n10. For subject with Type 2 Diabetes only: Is on stable dose of anti-diabetic medication (other than insulin) (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists\u002Fmimetics, metformin, SGLT2 inhibitors) for the last 3 months prior to screening. NB: Subject should not change type or dose of medication during the course of the study.\n11. For Israel only: Subject, Parents(s)\u002Flegal guardian(s) is fluent in English.\n\nExclusion Criteria:\n\n1. Has Addison's disease, growth hormone deficiency, hypopituitarism or definite gastroparesis, uncontrolled coeliac disease, uncontrolled thyroid disorder, or poorly controlled asthma, per investigator judgment.\n2. For subjects with Type 1 Diabetes only: Is using any anti-diabetic medication other than insulin 6 months before screening or plan on using during the study (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists\u002Fmimetics, metformin, SGLT2 inhibitors).\n3. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any chronically oral, injectable, or IV glucocorticoids during the course of the study, per investigator judgement\n4. Has had renal failure defined by creatinine clearance \\\u003C30 ml\u002Fmin, as assessed by local lab test ≤ 6 months before screening or performed at screening at local lab, as defined by the creatinine-based Cockcroft, CKD-EPI or MDRD equations.\n5. Has active or severe retinopathy in the last 6 months before screening\n6. Has any unresolved adverse skin conditions in the area of sensor placement (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).\n7. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.\n8. History of 2 or more DKA events in the last 3 months before screening.\n9. Has had Hyperosmolar Hyperglycemic State (HHS) in the last 6 months before screening.\n10. Is using hydroxyurea at time of screening or plans to use it during the study\n11. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study.\n12. Women who are breastfeeding.\n13. Is actively participating in an investigational study (drug or device) wherein he\u002Fshe has received treatment from an investigational study drug or device in the last 2 weeks before screening, as per investigator judgment.\n14. Subject is currently abusing illicit drugs, marijuana, alcohol or prescription drugs (other than nicotine), per investigator judgment.\n15. Subject, Parent(s)\u002Flegal guardian(s) are part of research staff involved with the study.\n16. Subject, Parent(s)\u002Flegal guardian (s) are legally incompetent, illiterate, or vulnerable.","2 Years",{"count":134,"type":20},116,[23],"This study will demonstrate the safety and performance of the Novel Medtronic Experimental Automated Insulin Delivery system named MiniMed™ NMX8 system in people living with insulin-requiring diabetes in comparison with the MiniMed™ 780G system.",[55],"2025-11-11",{"date":140,"type":32},"2025-11-13",{"date":142,"type":20},"2026-06-15",{"date":144,"type":20},"2027-03-17",{"name":38,"class":39},""]